All In Biotech

Drug Trial Radar · NCT07382908

Bioequivalence Study of BGM0504 Injection

A Single-Center, Single-Dose, Randomized, Open-Label, Single-Period, Parallel Bioequivalence Study of BGM0504 Injection in Overweight/Obese Participants

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

144

Actual

Start

Dec 29, 2025

Primary completion

Apr 9, 2026

Study completion Apr 9, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the bioequivalence of a single subcutaneous injection of BGM0504 multi-dose pen (experimental formula T1) and BGM0504 single-dose pen (experimental formula T2) with BGM0504 single-dose pen (reference formula R).

Conditions

  • Overweight/Obesity

Interventions

  • BGM0504 Injection multi-dose penDrug

    5 mg, single subcutaneous injection in the abdominal region

  • BGM0504 Injection single-dose penDrug

    5 mg, single subcutaneous injection in the abdominal region

  • BGM0504 Injection single-dose penDrug

    5 mg, single subcutaneous injection in the abdominal region

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak Plasma Concentration (Cmax)Time frame: 0 to 672 hours
  2. Area under the plasma concentration versus time curve (AUC)0-tTime frame: 0 to 672 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.